Recent Updates
Recently added Catalysts

loratadine; montelukast

Phase 3

Rhinitis, Allergic, Seasonal | Small molecule | Respiratory |Organon & Co.|Last Updated: Aug 15, 2024

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindUNCONTROLLED
Total Trials1
Total Enrollment1,095

FDA Designations

No designations recorded

Clinical trial landscape

loratadine; montelukast · 1 trial · 1 indication

Phase 3 1
NCT00319995Effects of Loratadine/Montelukast vs Pseudoephedrine and Placebo in Patients With Seasonal Allergic Rhinitis (Study P04095) (COMPLETED)Rhinitis, Allergic, Seasonal
COMPLETED1,095 Analytics
PHASE3COMPLETED
Effects of Loratadine/Montelukast vs Pseudoephedrine and Placebo in Patients With Seasonal Allergic Rhinitis (Study P04095) (COMPLETED)
Rhinitis, Allergic, SeasonalUnlock trial analytics

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT

Interventions

NameTypeDescription
loratadine; montelukastDRUG -
Unlock Study Design Details

Eligibility Criteria

Age Range15 Years to N/A
SexALL
Healthy VolunteersNo

Inclusion Criteria: * Aged 15 years or older, of either sex and of any race. * At least a 2-year documented history of SAR with symptoms during the study season. * A positive skin-prick test response to seasonal * Clinically symptomatic at Screening and at the Baseline Visits * General good health....

Unlock Eligibility Criteria